Alto Neuroscience ANRO Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$26.24M-62.1% | -$16.18M-14.1% | -$14.18M+19.9% | -$17.71M-16.7% | -$15.17M+0.2% | ||
| $184K+17.2% | $157K-21.5% | $200K+100% | $100K-41.5% | $171K+0.6% | ||
| $2.82M+45.1% | $1.95M-11.1% | $2.19M+9.2% | $2.01M+1.9% | $1.97M+25.7% | ||
| -$9K— | $0+100% | -$114K-11,300% | -$1K+97.6% | -$41K-36.7% | ||
| $1.49M— | —— | $461K+42.7% | $323K+221% | -$266K— | ||
| -$1.75M— | —— | —— | —— | -$2.7M-757% | ||
| $4.13M+730% | -$656K— | —— | —— | $1.69M— | ||
| $200K+1.5% | $197K+1.0% | $195K+1.6% | $192K+1.1% | $190K-10.0% | ||
| $0— | $0— | $0— | $0+100% | -$681K— | ||
| -$27.09M-135% | -$11.52M-16.1% | -$9.92M+28.0% | -$13.78M+16.8% | -$16.56M-27.1% | ||
| $556K— | —— | —— | —— | $24K-95.3% | ||
| -$556K— | —— | —— | —— | -$24K+95.3% | ||
| $0— | —— | —— | —— | $10.21M— | ||
| $6K-98.3% | $352K+130% | $153K— | $0-100% | $198K+304% | ||
| $190K— | —— | —— | —— | —— | ||
| $0— | —— | —— | —— | $127K— | ||
| $114.94M+129% | $50.19M+32,701% | $153K-75.0% | $613K-93.3% | $9.13M+18,527% | ||
| -$16K-1,500% | -$1K+75.0% | -$4K-33.3% | -$3K+86.4% | -$22K— | ||
| $87.28M+126% | $38.67M+496% | -$9.77M+25.8% | -$13.17M-76.2% | -$7.48M— | ||
| $342K-19.5% | $425K-8.6% | $465K+1.3% | $459K+47.6% | $311K+25.4% | ||
| $184K+17.2% | $157K-21.5% | $200K+50.4% | $133K-22.2% | $171K+0.6% | ||
| $116K+27.5% | $91K-18.8% | $112K+34.9% | $83K+102% | $41K+583% | ||
| -$1.75M— | —— | —— | —— | -$2.7M-757% | ||
| $4.13M+730% | -$656K— | —— | —— | $1.69M— | ||
| $206K+17.7% | $175K-8.9% | $192K+5.5% | $182K+1.1% | $180K+83.7% | ||
| $200K+1.5% | $197K+1.0% | $195K+1.6% | $192K+1.1% | $190K-10.0% | ||
| $4.88M— | —— | —— | —— | $0— | ||
| $0— | —— | —— | —— | $127K— | ||
| $0— | —— | —— | $137K-67.3% | $419K— | ||
| $120M— | —— | —— | —— | $0— | ||
| $941K-74.8% | $3.73M— | —— | —— | $0+100% | ||
| $0— | —— | —— | —— | $19.69M— | ||
| $0— | —— | —— | —— | $524K— | ||
| $233K— | —— | —— | —— | $0— | ||
| $0— | —— | —— | —— | $138K+6,800% | ||
| -$27.65M-140% | -$11.52M-16.1% | -$9.92M+28.0% | -$13.78M+16.9% | -$16.58M-22.6% | ||
| -$27.65M-140% | -$11.52M-16.1% | -$9.92M+28.0% | -$13.78M+16.9% | -$16.58M-22.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Alto Neuroscience generate?
- Alto Neuroscience (ANRO) generated -$62.3M in operating cash flow over the trailing twelve months.
- What is Alto Neuroscience's free cash flow?
- After $2.1M of capital expenditures, Alto Neuroscience's free cash flow was -$62.9M over the trailing twelve months, down 14.6% year over year.
- Where does Alto Neuroscience's cash flow data come from?
- Every line is extracted from Alto Neuroscience's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.